We are pleased to announce a new collaboration with Solid IO 📣.
As we advance our oncology pipeline, understanding how our antibody-based cancer therapies perform in human tumor tissue is an important step. Working with Solid IO allows us to generate functional data directly in human tumor samples, complementing the preclinical data we have gathered so far.
“Understanding how our therapies perform in human tumor tissue is highly valuable as we advance our oncology pipeline. Through this collaboration with Solid IO, we aim to gain functional insights that complement our existing preclinical data and help guide our development decisions.”
~ Peter Schiemann, CEO, Ymmunobio
We thank the Solid IO team for their support and look forward to working together on the next steps in developing new cancer therapies.
Read more about the collaboration on the Solid IO blog.
